



Clean copies of the claims after entry of this amendment

1. (As originally submitted) A compound of the formula I or formula

II




(I)



(II)

in which A is selected from the group consisting of



one of R_1 and R_2 is selected from H, OH and OCH_3 , and the other of R_1 and R_2 is selected from OH and OCH_3 ;

one of R_3 and R_4 is selected from H, OH and OCH_3 , and the other of R_3 and R_4 is selected from OH and OCH_3 ;

provided that at least one of the pairs R_1 , R_2 and R_3 , R_4 are both OH;


R_5 is selected from OH and OCH_3 ; and

----- denotes a single or double bond;

or a pharmaceutically acceptable salt or prodrug thereof;


with the proviso that

(a) when A is



and R_3 and R_4 are both OH then R_2 is other than H; and


(b) when A is




and R_3 and R_4 are both OH and R_2 is OCH_3 , then R_1 is other than H or OCH_3 .

2. (As originally submitted) A compound according to claim 1, wherein
 one of R_1 and R_2 is selected from H and OH, and the other of R_1 and R_2 is OH;
 one of R_3 and R_4 is selected from H and OH, and the other of R_3 and R_4 is OH;
 provided that at least one of the pairs R_1, R_2 and R_3, R_4 are both OH;
 R_5 is OH; and
 ----- denotes a single or double bond.

3. (As originally submitted) A compound according to claim 1 of the formula (IA) or (IIA)




(IA)




(IIA)

wherein A is as defined in claim 1;
 R_2 is H, and R_1 is selected from OH and OCH_3 ;
 R_3 and R_4 are each OH;
 R_5 is selected from OH and OCH_3 ; and
 ----- denotes a single or double bond.

4. (As originally submitted) A compound according to claim 1 of the formula (IB) or (IIB)



(IB)



(IIB)

wherein A is as defined in claim 1;


R₁ and R₂ are each OH;

R₃ is H, and R₄ is selected from OH and OCH₃;

R₅ is selected from OH and OCH₃; and

----- denotes a single or double bond.


5. (As originally submitted) A compound according to claim 1 which is 5-hydroxy-O-demethylangolesin (5-hydroxy-O-Dma) [1-(2, 4, 5-trihydroxyphenyl)-2-(4-hydroxyphenyl)-propan-1-one] having the structure (IV):



(IV)

or a pharmaceutically acceptable salt or prodrug thereof.

6. (As originally submitted) A compound according to claim 1 which is 3'-hydroxy-O-demethylangolesin (3'-hydroxy-O-Dma) [1-(2, 4, dihydroxypyphenyl)-2-(3, 4-dihydroxyphenyl)-propan-1-one] having the structure (V):




(V)

or a pharmaceutically acceptable salt or prodrug thereof.


7. (As originally submitted) A compound according to claim 1 which is 3'-hydroxy-O-demethyldehydroangolesin (3'-hydroxydehydro-O-Dma) [1-(2, 4-

dihydroxyphenyl)-2-(3, 4-dihydroxyphenyl)-prop-2-en-1-one] having the structure (VI):




or a pharmaceutically acceptable salt or prodrug thereof.

8. (As originally submitted). A compound according to claim 1 which is 3'-hydroxy-dihydrodaidzein having the structure (VII):



or a pharmaceutically acceptable salt or prodrug thereof.

9. (As originally submitted) A compound according to claim 1 which is 1-(2, 4, 5-trihydroxyphenyl)-2-(4-hydroxyphenyl)-prop-2-en-1-one having the structure (VIII):



or a pharmaceutically acceptable salt or prodrug thereof.

10. (As originally submitted) A pharmaceutical composition comprising one or more compounds according to claim 1, in association with one or more pharmaceutically acceptable carriers, adjuvants, diluents and/or excipients.

11. (As originally submitted) A food or drink composition, which

contains one or more compounds according to claim 1.

12. (Cancelled without prejudice)
13. (Cancelled without prejudice)
14. (Cancelled without prejudice)
15. (Cancelled without prejudice)
16. (Cancelled without prejudice)
17. (Cancelled without prejudice)
18. (Cancelled without prejudice)
19. (Cancelled without prejudice)
20. (Cancelled without prejudice)
21. (Cancelled without prejudice)
22. (Cancelled without prejudice)
23. (Cancelled without prejudice)